Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Expert Opinion on Drug Discovery
|
February 16, 2025
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Journal of Medicinal Chemistry
|
July 30, 2024
Structural and Physicochemical Features of Oral PROTACs
Markus Schade, James S Scott, Thomas G Hayhow, et al.
Neuropharmacology
|
January 25, 2006
The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone
John R Atack, Andy Pike, George Marshall, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 3, 2020
Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors
Bernard Barlaam, Scott Boiko, Scott Boyd, et al.
Journal of Medicinal Chemistry
|
July 11, 2024
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer
Sharan K Bagal, Peter C Astles, Coura Diène, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 30, 2020
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase
Sameer P Kawatkar, Bernard Barlaam, Paul Kemmitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.
Journal of Medicinal Chemistry
|
April 10, 2019
Design and Identification of a Novel, Functionally Subtype Selective GABA<sub>A</sub> Positive Allosteric Modulator (PF-06372865)
Robert M Owen, David Blakemore, Lishuang Cao, et al.
British Journal of Pharmacology
|
December 8, 2017
Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865
Sarah A Nickolls, Rachel Gurrell, Guido van Amerongen, et al.
Neuro-Oncology
|
December 24, 2025
Subtype selective PET imaging of PARP1 binding in non-human primates, healthy volunteers and patients with glioblastoma using [11C]AZ14193391
Zsolt Cselényi, Aurelija Jucaite, Giuseppe Stragliotto, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Expert Opinion on Drug Discovery
|
February 16, 2025
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Journal of Medicinal Chemistry
|
July 30, 2024
Structural and Physicochemical Features of Oral PROTACs
Markus Schade, James S Scott, Thomas G Hayhow, et al.
Neuropharmacology
|
January 25, 2006
The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone
John R Atack, Andy Pike, George Marshall, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 3, 2020
Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors
Bernard Barlaam, Scott Boiko, Scott Boyd, et al.
Journal of Medicinal Chemistry
|
July 11, 2024
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer
Sharan K Bagal, Peter C Astles, Coura Diène, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 30, 2020
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase
Sameer P Kawatkar, Bernard Barlaam, Paul Kemmitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.
Journal of Medicinal Chemistry
|
April 10, 2019
Design and Identification of a Novel, Functionally Subtype Selective GABA<sub>A</sub> Positive Allosteric Modulator (PF-06372865)
Robert M Owen, David Blakemore, Lishuang Cao, et al.
British Journal of Pharmacology
|
December 8, 2017
Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865
Sarah A Nickolls, Rachel Gurrell, Guido van Amerongen, et al.
Neuro-Oncology
|
December 24, 2025
Subtype selective PET imaging of PARP1 binding in non-human primates, healthy volunteers and patients with glioblastoma using [11C]AZ14193391
Zsolt Cselényi, Aurelija Jucaite, Giuseppe Stragliotto, et al.
Page
of 3